Background
Phase IIIb, multicenter, open-label, randomized, noninferiority trial (Sarode 2013). 202 nonsurgical patients on vitamin K antagonist (VKA) therapy presenting with acute major bleeding requiring urgent anticoagulation reversal. Patients were randomized to 4-factor prothrombin complex concentrate (4F-PCC; KCentra/Beriplex) — containing factors II, VII, IX, and X plus proteins C and S — or plasma (FFP). The trial was designed to demonstrate noninferiority of 4F-PCC to plasma for hemostatic efficacy while establishing superior INR correction, addressing the practical limitation that large plasma volumes are required for VKA reversal and plasma carries risks of transfusion-associated complications and delays from thawing/cross-matching.
Interventions and follow up
Arm A: 4F-PCC (KCentra), INR-based weight-adjusted dosing: INR 2–3.9 → 25 IU/kg; INR 4–6 → 35 IU/kg; INR >6 → 50 IU/kg, max 5,000 IU; IV single infusio
Arm B: Plasma (FFP), same INR-based dosing: INR 2–3.9 → 10 mL/kg; INR 4–6 → 15 mL/kg; INR >6 → 20 mL/kg; all patients also received vitamin K 1–10 mg IV
Primary endpoint: 24-hour hemostatic efficacy (clinical assessment) AND INR ≤1.3 at 30 min after infusion (co-primary)
mFollow up: 45 day
Arm B: Plasma (FFP), same INR-based dosing: INR 2–3.9 → 10 mL/kg; INR 4–6 → 15 mL/kg; INR >6 → 20 mL/kg; all patients also received vitamin K 1–10 mg IV
Primary endpoint: 24-hour hemostatic efficacy (clinical assessment) AND INR ≤1.3 at 30 min after infusion (co-primary)
mFollow up: 45 day
Results
Effective hemostasis at 24h: 72.4% (4F-PCC) vs 65.4% (plasma) — noninferior (difference 7.1%, 95% CI −5.8 to 19.9)
INR ≤1.3 at 30 min after infusion: 62.2% (4F-PCC) vs 9.6% (plasma) — 4F-PCC SUPERIOR (difference 52.6%, 95% CI 39.4–65.9)
Assessed coagulation factors: Significantly higher in 4F-PCC arm at 0.5–3h (P<.02 for all factors)
Median baseline INR: 3.90 (4F-PCC) vs 3.60 (plasma)
INR ≤1.3 at 30 min after infusion: 62.2% (4F-PCC) vs 9.6% (plasma) — 4F-PCC SUPERIOR (difference 52.6%, 95% CI 39.4–65.9)
Assessed coagulation factors: Significantly higher in 4F-PCC arm at 0.5–3h (P<.02 for all factors)
Median baseline INR: 3.90 (4F-PCC) vs 3.60 (plasma)
Adverse events
Main adverse events: Safety was similar between groups: AEs (any) 64% (4F-PCC) vs 65% (plasma). Thromboembolic events: 7% (4F-PCC) vs 8% (plasma) — not significantly different. Deaths: 10 (4F-PCC) vs 13 (plasma) — not different; most were related to underlying conditions. Transfusion-associated complications (TACO, TRALI) not separately tabulated but numerically fewer in 4F-PCC arm. Infusion-related reactions: rare in both arms.
Conclusions
4F-PCC achieves noninferior 24-hour clinical hemostasis and markedly superior INR correction (62% vs 10% achieving INR ≤1.3 at 30 min) compared to plasma for urgent VKA reversal, with a comparable safety profile, establishing 4F-PCC as the preferred agent for urgent VKA reversal in major bleeding.
Key Limitations
Key Limitations: Open-label design (blinding not feasible due to volume differences). Clinical hemostatic efficacy is a subjective composite endpoint. The trial enrolled nonsurgical patients only — surgical/trauma hemorrhage may behave differently. Vitamin K was given to all patients, which contributes to eventual factor replenishment regardless of reversal agent; the INR superiority of 4F-PCC is most clinically meaningful in the first few hours. The 4F-PCC dose algorithm (INR-based, weight-adjusted) is important for correct clinical use; under-dosing is a common real-world error. Thromboembolic event rates (7–8%) reflect background risk in anticoagulated patients with major bleeding rather than causation by the reversal agents.
Clinical Context
Sarode 2013 supported FDA approval of KCentra (4F-PCC) in 2013 for urgent warfarin reversal. 4F-PCC is now the standard of care for VKA reversal in major/life-threatening bleeding (intracranial hemorrhage, GI bleed, surgical emergency), per ACCP, ISTH, and AHA guidelines. Advantages over plasma: smaller volume (reduces TACO/TRALI risk), faster infusion (~15 min vs 30–60 min for 4 units FFP), no thawing delay, no need for ABO compatibility. Vitamin K must always be co-administered. Activated PCC (FEIBA) is reserved for factor VIII inhibitors or acquired hemophilia — not for VKA reversal. For DOAC reversal, separate agents are used: idarucizumab (Praxbind) for dabigatran (REVERSE-AD), andexanet alfa (Andexxa) for anti-Xa DOACs (ANNEXA-4).
References